An Update on Higher Risk Myelodysplastic Syndromes

被引：0
|
作者：
Hochman, Michael J. [1 ]
DeZern, Amy E. [1 ]
机构：
[1] Johns Hopkins Univ, Div Hematol Malignancies & Bone Marrow Transplant, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
Myeloid malignancies; clonal cytopenia; prognostication; molecular genetics; response criteria; PROGNOSTIC SCORING SYSTEM; LEUKEMIA; CPX-351; POTENT;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S21 / S25
页数：5
相关论文
共 50 条
  • [1] An update on treatment of higher risk myelodysplastic syndromes
    Rahme, Ramy
    Ades, Lionel
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (01) : 61 - 70
  • [2] SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
    Hochman, Michael J.
    DeZern, Amy E.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09): : 573 - 582
  • [3] Management of patients with higher risk myelodysplastic syndromes
    Fukumoto, JS
    Greenberg, PL
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 56 (02) : 179 - 192
  • [4] The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
    Silverman, L. R.
    Fenaux, P.
    Mufti, G. J.
    Santini, V.
    Hellstrom-Lindberg, E.
    Gattermann, N.
    Sanz, G.
    List, A. F.
    Gore, S. D.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    [J]. ECANCERMEDICALSCIENCE, 2008, 2
  • [5] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    Dinmohamed, A. G.
    van Norden, Y.
    van de Loosdrecht, A. A.
    Jongen-Lavrencic, M.
    [J]. LEUKEMIA, 2016, 30 (08) : 1795 - +
  • [6] Overview of the Management of Higher-Risk Myelodysplastic Syndromes
    Singh, Abhay
    Carraway, Hetty E.
    [J]. CANCER JOURNAL, 2023, 29 (03): : 160 - 167
  • [7] Therapeutic approaches for the management of higher risk myelodysplastic syndromes
    Wang, Chen
    Sallman, David A.
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 511 - 524
  • [8] Impact of Iron Overload in Higher Risk Myelodysplastic Syndromes
    Komrokji, S.
    Al Ali, Najla H.
    Corrales-Yepez, Maria
    Padron, Eric
    Epling-Burnette, Pearlie K.
    Lancet, Jeffrey E.
    List, Alan F.
    [J]. BLOOD, 2011, 118 (21) : 1197 - 1197
  • [9] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    A G Dinmohamed
    Y van Norden
    A A van de Loosdrecht
    M Jongen-Lavrencic
    [J]. Leukemia, 2016, 30 : 1795 - 1796
  • [10] Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
    Garcia-Manero, Guillermo
    Chien, Kelly S.
    Montalban-Bravo, Guillermo
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (11) : 1399 - 1420
12345